Mallinckrodt sees nuclear imaging revenues drop in Q3

Pharmaceutical developer Mallinckrodt's Nuclear Imaging business segment produced lower revenues in its 2016 fiscal third quarter.

For the period (end-June 24), the company recorded Nuclear Imaging segment sales of $104 million, down 4.4% on a nominal basis and down 4.7% on a constant-currency basis from the $108.8 million reported in the third quarter of 2015.